Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management34
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder25
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia22
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?22
New drugs targeting calcitonin gene-related peptide for the management of migraines18
A review of phase II and III drugs for the treatment and management of endometriosis18
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials16
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review15
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials14
Emerging injectable therapies for osteoarthritis14
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials14
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?13
Emerging medicines to improve the basic defect in cystic fibrosis12
Emerging biological treatments for asthma12
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia12
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape11
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials10
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms10
A review of emerging factor XI inhibitors9
Emerging drugs for the treatment of herpetic keratitis9
Cannabinoid treatment for the symptoms of autism spectrum disorder9
Emerging antiviral therapies and drugs for the treatment of influenza8
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder8
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion8
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma8
Emerging tyrosine kinase inhibitors for head and neck cancer8
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?8
Correction8
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials7
The role of HER2-targeted therapy in urothelial carcinomas7
Emerging drugs for the treatment of irritability associated with autism spectrum disorder7
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis7
How will tovorafenib change our treatment of pediatric low-grade glioma?7
Gene therapy for wet AMD: a paradigm shift in the standard of care6
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials6
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa6
Current and emerging drug treatment strategies to tackle sickle cell anemia6
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis6
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results6
Correction6
What can we expect from a combination of datopotamab deruxtecan, carboplatin, and pembrolizumab for brain metastases from non-small cell lung cancer?6
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis6
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma6
Emerging drugs in the treatment of chronic cough6
Emerging drugs for the treatment of inflammatory bowel disease6
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?6
Emerging drugs for the treatment of diabetic nephropathy5
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E5
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma5
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II5
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma5
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma5
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond5
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update4
Cancer drugs with high repositioning potential for Alzheimer’s disease4
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder4
Emerging drugs for the treatment of major depressive disorder4
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers4
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials4
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’4
Emerging drugs for the treatment of alopecia areata4
0.087476968765259